-
Dec 3, 2024 | 
businessandamerica.com | Dana P. Goldman
President-elect Donald Trump has nominated Schaeffer Institute Scholar Jay Bhattacharya as The National Institutes of Health director. I can’t think of a better choice. Source link
-
Aug 2, 2024 | 
jamanetwork.com | Christopher A. Scannell |John A. Romley |Rebecca Myerson |Dana P. Goldman
Introduction Semaglutide was first approved under the brand name Ozempic (Novo Nordisk) as a weekly injection by the US Food and Drug Administration (FDA) in 2017 and is a first-line treatment for patients with type 2 diabetes at high cardiovascular risk.1 Alongside evidence of semaglutide’s cardiovascular and weight loss benefits,2 the FDA approved Rybelsus (Novo Nordisk), an oral formulation for the treatment of type 2 diabetes, in 2019, and Wegovy (Novo Nordisk), another injectable...
-
May 23, 2024 | 
jamanetwork.com | John A. Romley |Rebecca Myerson |Dana P. Goldman |A. Mark Fendrick
Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing Although vaccinations prevent morbidity and mortality among Medicare beneficiaries, uptake of vaccines recommended by the Advisory Committee on Immunization Practices covered by Medicare Part D (ie, shingles, tetanus, diphtheria, pertussis, and hepatitis A and B) is suboptimal.1 Unlike commercially insured individuals who have no cost sharing for recommended vaccinations, in 2021, Medicare...
-
Apr 22, 2024 | 
linkedin.com | Dana P. Goldman
In health care, the term “value” gets lobbed about quite loosely. It is easy to forget that centuries of economic thought have gone into rigorously examining how worth is determined in a marketplace. Unfortunately, Congress conveniently ignores these economic lessons -- with a little help from Ivy League researchers. The latest grenade came from Bernie Sanders.
-
Apr 3, 2024 | 
statnews.com | Dana P. Goldman |Alison Ward
The latest weight loss drugs are good. Really good. They can save lives and could literally remake American health. But rather than celebrate, we’re having a political conversation that is all about price controls. is timely: Beware the fool who knows the price of everything and the value of nothing. We and several of our colleagues have studied the new weight loss drugs, known as GLP-1s, like Wegovy (semaglutide) and Zepbound (tirzepatide), and modeled their impact.
-
Dec 9, 2023 | 
thehill.com | Dana P. Goldman |Don Simborg |Immanuel Thangaraj
The case for the Biden administration’s initiative to eradicate deadly hepatitis C is simple. It aims to rescue millions of lives, in line with the World Health Organization’s target of eliminating the disease by 2030. Biden’s approach in the United States builds on novel subscription models employed in Louisiana and Washington that sought to expand access to cures.
-
Jul 24, 2023 | 
jamanetwork.com | Rebecca Myerson |Dana P. Goldman |John A. Romley
Medicare beneficiaries’ out-of-pocket costs for insulin exceeded $1 billion in 2020 vs $236 million in 2007.1 High costs lead some patients with diabetes to reduce adherence to insulin, increasing the risk of adverse health outcomes.2-4 Although efforts to cap patients’ cost sharing for insulin have existed in some states since 2020, and in certain Medicare Part D plans since 2021, in January 2023 the Inflation Reduction Act5 capped cost sharing for insulin at $35 for a 1-month supply for all...
-
May 26, 2023 | 
thehill.com | Dana P. Goldman |Darius Lakdawalla
The Inflation Reduction Act of 2022 makes the most dramatic changes to American healthcare since the Affordable Care Act 13 years ago. Of particular note, it empowers Medicare to begin setting ceilings on prescription drug prices. But the success of the IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
-
May 26, 2023 | 
jamanetwork.com | David C. Grabowski |Anuraag R. Kansal |Dana P. Goldman
Key PointsQuestion Is a cancer history associated with the receipt of disability insurance, income, employment, and medical spending in the US? Findings In this cross-sectional study of 39 439 respondents to the Medical Expenditure Panel Study, cancer survivors had a lower likelihood of employment and a greater likelihood of a work-limiting disability compared with respondents without a history of cancer.
-
Apr 18, 2023 | 
healthpolicy.usc.edu | Alison Ward |Bryan Tysinger |Phuong Nguyen |Phương Nguyên |Dana P. Goldman
Schaeffer Center White Paper Series | DOI: 10.25549/4rf9-kh77Obesity affects almost half of U.S. adults and is associated with increased disability, disease and pain that reduces quality of life and increases future healthcare spending. Yet issues with the safety and effectiveness of earlier treatments in the 1990s led Congress to specifically prohibit Medicare from covering obesity treatments in 2006 as part of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA).
